Genmab value drops by over USD 1.5bn after royalties defeat

After a ruling against Genmab encompassing two different royalty issues with partner Janssen, the market value of the firm has dropped by DKK 10.8bn (USD 1.58bn).

Photo: Tuala Hjarnø / Genmab / PR

Since trading opened on Friday, Genmab’s market value has dropped by DKK 10.8bn (USD 1.58bn), as news broke that arbitrators had ruled in Janssen’s favor in a royalties dispute between the two firms.

One of the issues concerned lost royalty incomes, which US-based Janssen had been withholding from Genmab in order to pay royalties to Halozyme Therpeutics since 2020. Halozyme provided the technology to allow faster treatments with Darzalex in a new product called Darzalex Faspro.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs